目的 探讨儿童Alport综合征（Alport syndrome，AS）致病基因COL4A5基因型与临床表型的特点。 方法 回顾性分析19例存在COL4A5基因突变的AS患儿的基因检测结果和临床资料。 结果 19例COL4A5基因突变导致的AS患儿中，1例（5%）存在COL4A5基因新突变位点c.3372A>G(p.P1124=)，其表现为AS合并IgA血管炎肾炎；3例（16%）存在COL4A5基因大片段缺失，其中2例（例7为新突变位点：loss51-53）起病即存在肉眼血尿和蛋白尿，1例（例13，存在新突变位点：loss3-53）仅有镜下血尿；其余15例（79%）患儿均为AS的常见临床表型，其中7例存在COL4A5基因新突变位点。3例（16%）患儿合并COL4A4基因突变，1例（5%）合并COL4A3基因突变，在这些双基因突变患儿中有2例起病即为肉眼血尿合并蛋白尿。 结论 该研究拓展了AS致病基因COL4A5的基因型和表型谱；发生COL4A5基因大片段缺失突变或COL4A5合并COL4A3或COL4A4的双基因突变患儿的临床表现更严重。
Abstract
Objective To investigate the genotypes of the pathogenic gene COL4A5 and the characteristics of clinical phenotypes in children with Alport syndrome (AS). Methods A retrospective analysis was performed for the genetic testing results and clinical data of 19 AS children with COL4A5 gene mutations. Results Among the 19 children with AS caused by COL4A5 gene mutations, 1 (5%) carried a new mutation of the COL4A5 gene, i.e., c.3372A>G(p.P1124=) and presented with AS coexisting with IgA vasculitis nephritis; 3 children (16%) had large fragment deletion of the COL4A5 gene, among whom 2 children (case 7 had a new mutation site of loss51-53) had gross hematuria and albuminuria at the onset, and 1 child (case 13 had a new mutation site of loss3-53) only had microscopic hematuria, while the other 15 children (79%) had common clinical phenotypes of AS, among whom 7 carried new mutations of the COL4A5 gene. Among all 19 children, 3 children (16%) who carried COL4A5 gene mutations also had COL4A4 gene mutations, and 1 child (5%) had COL4A3 gene mutations. Among these children with double gene mutations, 2 had gross hematuria and proteinuria at the onset. Conclusions This study expands the genotype and phenotype spectrums of the pathogenic gene COL4A5 for AS. Children with large fragment deletion of the COL4A5 gene or double gene mutations of COL4A5 with COL4A3 or COL4A4 tend to have more serious clinical manifestations.
关键词
Alport综合征 /
COL4A5基因 /
基因型 /
临床表型 /
儿童
Key words
Alport syndrome /
COL4A5 gene /
Genotype /
Clinical phenotype /
Child
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
1 Savige J, Storey H, Watson E, et al. Consensus statement on standards and guidelines for the molecular diagnostics of Alport syndrome: refining the ACMG criteria[J]. Eur J Hum Genet, 2021, 29(8): 1186-1197. PMID: 33854215. PMCID: PMC8384871. DOI: 10.1038/s41431-021-00858-1.
2 Matthaiou A, Poulli T, Deltas C. Prevalence of clinical, pathological and molecular features of glomerular basement membrane nephropathy caused by COL4A3 or COL4A4 mutations: a systematic review[J]. Clin Kidney J, 2020, 13(6): 1025-1036. PMID: 33391746. PMCID: PMC7769542. DOI: 10.1093/ckj/sfz176.
3 赵颖玲, 于力. Alport综合征的临床表现及诊疗进展[J]. 罕少疾病杂志, 2022, 29(4): 1-4. DOI: 10.3969/j.issn.1009-3257.2022.04.001.
4 Kashtan CE. Alport syndrome: achieving early diagnosis and treatment[J]. Am J Kidney Dis, 2021, 77(2): 272-279. PMID: 32712016. DOI: 10.1053/j.ajkd.2020.03.026.
5 Alport综合征诊疗共识专家组. Alport综合征诊断和治疗专家推荐意见[J]. 中华肾脏病杂志, 2018, 34(3): 227-231. DOI: 10.3760/cma.j.issn.1001-7097.2018.03.014.
6 Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology[J]. Genet Med, 2015, 17(5): 405-424. PMID: 25741868. PMCID: PMC4544753. DOI: 10.1038/gim.2015.30.
7 王卫平, 孙锟, 常立文, 等. 儿科学[M]. 9版. 北京: 人民卫生出版社, 2018: 296.
8 安晓刚, 张琰琴, 丁洁, 等. Alport综合征单中心临床诊治状况分析[J]. 中华儿科杂志, 2016, 54(9): 669-673. PMID: 27596081. DOI: 10.3760/cma.j.issn.0578-1310.2016.09.008.
9 于小勇. 2022年美国医学遗传学与基因组学学会/分子病理学协会Alport综合征管理和基因检测指南[J]. 陕西医学杂志, 2023, 52(3): 243-251. DOI: 10.3969/j.issn.1000-7377.2022.03.001.
10 Mencarelli MA, Heidet L, Storey H, et al. Evidence of digenic inheritance in Alport syndrome[J]. J Med Genet, 2015, 52(3): 163-174. PMID: 25575550. DOI: 10.1136/jmedgenet-2014-102822.
11 Choi M, Anistan YM, Eckardt KU, et al. Possible digenic disease in a Caucasian family with COL4A3 and COL4A5 mutations[J]. Nephron, 2019, 141(3): 213-218. PMID: 30661074. DOI: 10.1159/000495764.
12 Zhang Y, Ding J, Zhang H, et al. Effect of heterozygous pathogenic COL4A3 or COL4A4 variants on patients with X-linked Alport syndrome[J]. Mol Genet Genomic Med, 2019, 7(5): e647. PMID: 30883042. PMCID: PMC6503168. DOI: 10.1002/mgg3.647.
13 胡宁宁, 戴选彤, 蒋更如, 等. 双基因突变型X连锁Alport综合征女性患者临床与遗传学特征分析[J]. 上海医学, 2021, 44(6): 434-442. DOI: 10.19842/j.cnki.issn.0253-9934.2021.06.016.
14 Savige J, Lipska-Zietkiewicz BS, Watson E, et al. Guidelines for genetic testing and management of Alport syndrome[J]. Clin J Am Soc Nephrol, 2022, 17(1): 143-154. PMID: 34930753. PMCID: PMC8763160. DOI: 10.2215/CJN.04230321.
15 Zhang X, Zhang Y, Zhang Y, et al. X-linked Alport syndrome: pathogenic variant features and further auditory genotype-phenotype correlations in males[J]. Orphanet J Rare Dis, 2018, 13(1): 229. PMID: 30577881. PMCID: PMC6303895. DOI: 10.1186/s13023-018-0974-4.
16 成艳辉. Alport综合征患儿临床表型与基因型分析[D]. 西安: 西安医学院, 2022.
17 Zhao X, Chen C, Wei Y, et al. Novel mutations of COL4A3, COL4A4, and COL4A5 genes in Chinese patients with Alport syndrome using next generation sequence technique[J]. Mol Genet Genomic Med, 2019, 7(6): e653. PMID: 30968591. PMCID: PMC6565573. DOI: 10.1002/mgg3.653.
18 Plant KE, Boye E, Green PM, et al. Somatic mosaicism associated with a mild Alport syndrome phenotype[J]. J Med Genet, 2000, 37(3): 238-239. PMID: 10777371. PMCID: PMC1734534. DOI: 10.1136/jmg.37.3.238.
19 Navarro-Cobos MJ, Balaton BP, Brown CJ. Genes that escape from X-chromosome inactivation: potential contributors to Klinefelter syndrome[J]. Am J Med Genet C Semin Med Genet, 2020, 184(2): 226-238. PMID: 32441398. PMCID: PMC7384012. DOI: 10.1002/ajmg.c.31800.
20 Queremel Milani DA, Chauhan PR. Genetics, Mosaicism[M]//StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2023.
基金
河南省重点研发与推广专项（科技攻关）项目（212102310441）。
PDF(1109 KB)
